IL-33 potentiates histaminergic itch

• Published in: Journal of allergy and clinical immunology Vol. 153; no. 3; pp. 852 - 859.e3
• Main Authors: Trier, Anna M., Ver Heul, Aaron M., Fredman, Avery, Le, Victoria, Wang, Zhen, Auyeung, Kelsey, Meixiong, James, Lovato, Paola, Holtzman, Michael J., Wang, Fang, Dong, Xinzhong, Ji, Andrew L., Kim, Brian S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2024
• Subjects: Animals; Chronic spontaneous urticaria; histamine; Histamine - metabolism; Histamine Antagonists; Humans; IL-13; IL-33; Interleukin-13 - genetics; Interleukin-13 - metabolism; Interleukin-33 - metabolism; itch; mast cell; Mice; Mice, Knockout; neuroimmunology; Pruritus - pathology; Quality of Life; Skin - pathology; itch; LM; histamine; ImmGen; CSU; mast cell; OSM; Chronic spontaneous urticaria; IL-13; C48/80; IL-33; neuroimmunology; His; scRNA-Seq; OVA; IL-33R; WT

[Display omitted] Itch is a common symptom that can greatly diminish quality of life. Histamine is a potent endogenous pruritogen, and while antihistamines are often the first-line treatment for itch, in conditions like chronic spontaneous urticaria (CSU), many patients remain symptomatic while rece...